Related Experiment Video

Updated: Sep 22, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

[Survival impact of previous statin therapy in patients hospitalized with COVID-19]

Eduardo Barge-Caballero1, Pedro J Marcos-Rodríguez2, Nieves Domenech-García3

  • 1Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España; Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España.

Medicina Clinica
|May 26, 2022
PubMed

Insights

Statin use before hospitalization for COVID-19 significantly reduced mortality. This benefit was most pronounced in patients with pre-existing coronary or extracardiac arterial disease, highlighting statins

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Statin therapy possesses immunomodulatory, anti-inflammatory, and anti-atherosclerotic properties.
  • These properties suggest a potential beneficial prognostic effect in patients with COVID-19.

Purpose of the Study:

  • To investigate the hypothesis that statin therapy improves outcomes in hospitalized COVID-19 patients.
  • To analyze the association between pre-admission statin use and mortality in COVID-19 patients.

Main Methods:

  • A single-center, observational, retrospective study of 1122 hospitalized COVID-19 patients (March-October 2020).
  • Propensity score matching and inverse probability of treatment weighting (IPTW) using Cox regression were employed.
  • Survival analysis compared outcomes between patients with and without prior statin treatment.

Main Results:

  • Prior statin treatment was associated with a significant reduction in mortality (Hazard Ratio: 0.76; 95% Confidence Interval: 0.59-0.97).
  • The greatest mortality reduction was observed in patients with coronary artery disease (HR: 0.32) and extracardiac arterial disease (HR: 0.45).
  • The median follow-up duration was 406 days.

Conclusions:

  • Pre-admission statin therapy is significantly associated with lower mortality in hospitalized COVID-19 patients.
  • The prognostic benefit of statins was more pronounced in patients with pre-existing coronary or extracardiac atherosclerotic disease.
Abstract

Keywords:
COVID-19EstatinasSARS-CoV-2StatinsSupervivenciaSurvival

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
900
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
37
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
24
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
47
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
44
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
34